Eton Pharmaceuticals Inc (ETON) Fair Value & Analysis

Healthcare · US · Market cap $1.0B · ISIN US29772L1089

What is Eton Pharmaceuticals Inc really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($2.44). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 16, 2026.

How to read this chart

60‑month range $2.02 – $64.43 · fair‑value band $1.39 – $2.44 · the $59.90 price screens above the $1.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Eton Pharmaceuticals Inc (ETON) currently trades at $59.90, while our model-based Fair Value estimate is $1.92, implying the stock looks roughly 3,015.3% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bull case: the Asset-Based group reads highest at a median of $6.14 per share, and 3 of the 15 models we run sit above the $59.90 price. Bear case: the Earnings-Based group reads lowest at $1.54, and 12 of the 15 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Eton Pharmaceuticals Inc generated revenue of $86.9M at a net margin of −1.7%. Revenue grew 40.4% year over year. It earns a return on equity of −5.4%. Net debt stands at $5.1M. Fundamentals as of Aug 16, 2026

Our scenario range runs from $1.39 (bear case) to $2.44 (bull case); at $59.90, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −97%, ETON screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: DCF Models ($41.09) versus Earnings-Based ($1.54). Highest evidence: FCF DCF (75).

Key figures & financial health

Quality Score breakdown

About the company

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

Full company description

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Eton Pharmaceuticals Inc reported revenue of $80.0M in FY2025 versus $21.8M in FY2021, a compound +38.3%/yr. Reported net income was −$4.6M in FY2025.

ETON screens 3,015% overvalued. Compare with Merck KGaA →

Peer Group

Drug Manufacturers - Specialty & Generic · 608 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 16, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions